Farletuzumab

N/A

Report date: 2025/08/13 20:02:02

Base Information

Drug NameFarletuzumab
Drug Alias NameAnti-GP-3 humanised mAb法利珠单抗法乐妥珠单抗FarletuzumabumAnti-GP3 humanised monoclonal antibody +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionFolate receptor alpha antagonists
TargetsFolate receptor alpha
Therapy Area/IndicationsSolid tumoursFallopian Tube NeoplasmsOvarian Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[30] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMorphotek Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMorphotek IncEisai IncEisai Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursFallopian Tube NeoplasmsOvarian Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG